Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PURETHAL Mites dose-ranging study in house dust mite allergic rhinitis
NL-OMON38151Phase 2Active, not recruiting
- Sponsor
- HAL Allergy Group
- Start
- Oct 2011
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Purethal in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and house dust mite allergy (5 arms), sponsored by HAL Allergy Group. Started Oct 2011; status: active, not recruiting.
02
Drugs
Purethal
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)house dust mite allergy
Beyond the preview
Go deeper on NL-OMON38151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38151.